research Hyperandrogenism in a set of triplets with modification of clinical course by hyperthyroidism
Hyperthyroidism can hide signs of high androgen levels in females.
Search
for
Sort by
Research
180-210 / 1000+ results research Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates
Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
research Synthesis of novel andostane-N-cyclohexyl-17-carboxamides, and their effect on the 5α-reductase isoform 2, the androgen receptor, and androgen-dependent glands
New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
research Influence of dietary linoleic acid (18:2, n6) on the effects of hyperthyroidism in Mus musculus
Dietary linoleic acid may help reduce hyperthyroidism effects.
research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
research Study Answers Some Questions about Androgen Suppression Pre-Radiation, but Not All
Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.
research Thallium poisoning. Diagnosis may be elusive but alopecia is the clue.
Alopecia is a key indicator of thallium poisoning.
research Solubilization and Solid‐State Characterization of a Poorly Soluble 5‐α Reductase Inhibitor
GI197111X is best dissolved in Capmul MCM for trials.
research Is 3α, 17β-androstanediol-glucuronide a diagnostic marker in women with androgenic manifestations?
3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.
research 414 A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer
BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
research ODP292 A Xanthomatous Hypophysitis: Always Think Twice Before Pituitary Resection.
Always consider xanthomatous hypophysitis before deciding on pituitary surgery.
research Spurenelementkonzentration im Haar bei Patienten mit Schilddrüsenerkrankungen
Trace element levels in hair differ in people with thyroid diseases.
research “Occult” ovarian Leydig cell tumor: when laboratory tells more than imaging
Blood tests can detect ovarian Leydig cell tumors when scans don't, and surgery can confirm and treat these tumors.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
The study investigated the effects of IMG-007, an anti-OX40 monoclonal antibody, on patients with severe alopecia areata (AA). In this phase 1b/2a open-label study, 29 participants received either 300 mg or 600 mg doses of IMG-007. The 600 mg group showed significant improvement in hair regrowth, with a progressive reduction in SALT scores up to week 36, while the 300 mg group showed little change. IMG-007 was well-tolerated, with only mild or moderate adverse events. Biomarker analysis revealed normalization of inflammatory gene expression and partial restoration of hair-associated keratin genes. These findings suggest that IMG-007 could be an effective treatment for AA by blocking OX40-OX40L signaling.
research Selective androgen receptor modulators: a critical appraisal
SARMs show promise but need more evidence to prove they're better than traditional androgens.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Synthesis, Anticancer and Molecular Docking Studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-Oxadiazole Analogues
The compound 4c showed strong potential as an anticancer agent.
research ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research Used Right, IV Arsenic Is Safe & Effective
Intravenous arsenic is safe and effective for treating certain blood cancers.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.
research 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
research An ovarian Leydig cell tumor of ultrasound negative in a postmenopausal woman with hirsutism and hyperandrogenism
A postmenopausal woman's hirsutism and high testosterone levels improved after surgery for an ovarian tumor not seen on ultrasound.
research Modeling of chronic radiation-induced cystitis in mice
Researchers developed a mouse model that successfully mimics the bladder damage seen in humans after radiation therapy.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Persistent radiation-induced alopecia in patients with central nervous system tumors and head and neck sarcomas.
Radiation therapy with chemotherapy can cause severe, long-lasting hair loss.
research Is growth hormone a radioprotective agent?
Growth hormone may protect skin from radiation damage.